Subject(s)
Bacteremia/drug therapy , Drug Resistance, Microbial , Drug Resistance, Multiple , Meningitis, Pneumococcal/drug therapy , Pneumococcal Infections/drug therapy , Streptococcus pneumoniae/drug effects , Anemia, Sickle Cell/complications , Bacteremia/complications , Cefotaxime/pharmacology , Cefotaxime/therapeutic use , Cephalosporins/administration & dosage , Cephalosporins/therapeutic use , Child , Drug Therapy, Combination/pharmacology , Drug Therapy, Combination/therapeutic use , Humans , Male , Meningitis, Pneumococcal/complications , Microbial Sensitivity Tests , Pneumococcal Infections/complications , Vancomycin/pharmacology , Vancomycin/therapeutic useABSTRACT
Bone mineral content, bone width, and their ratio were measured in patients with cystic fibrosis (CF) using monoenergetic photon absorptiometry. Serial measurements of the radius and ulna were made in 27 patients with CF and were compared with 968 age-matched controls. Demineralization was found in 37% of the boys and 63% of the girls. Patients under age 10 years had normal bone mineral content and nine of 15 patients aged 13 or older were demineralized (P less than .01). Demineralization correlated with the extent of weight reduction in patients (P less than .001). Patients most likely to be demineralized were adolescent girls. To our knowledge, this is the first report of bone mineral status of children with CF, and the results indicate that a sizable proportion of these patients may be demineralized without overt rickets.
Subject(s)
Bone Diseases/etiology , Bone and Bones/metabolism , Cystic Fibrosis/complications , Growth Disorders/etiology , Minerals/metabolism , Adolescent , Adult , Alkaline Phosphatase/blood , Bone Development , Bone Diseases/diagnosis , Bone Diseases/metabolism , Calcium/blood , Calcium/metabolism , Child , Child, Preschool , Cystic Fibrosis/metabolism , Densitometry , Female , Growth Disorders/metabolism , Humans , Male , Methods , Phosphorus/bloodABSTRACT
The combined use of amphotericin B and 5-fluorocytosine in the treatment of two children with Candida albicans meningitis is described. Therapy consisted of nine to 13 days of iv amphotericin B, combined with, or followed by six to nine weeks of oral 5-FC. Each organism was sensitive to 5-FC before starting therapy. Resistance did not develop during therapy. CSF administration was not necessary and toxic reactions were minimal and transient; neither patient has suffered a recurrence four years and 14 months, respectively, after discontinuance of therapy. The combination of short-term therapy with iv amphotericin B plus long-term oral 5-FC was successful in these two patients.